Guerbet leads entry into UK market with magnetic resonance imaging (MRI) agents
This article was originally published in Clinica
Executive Summary
French contrast agent manufacturer Guerbet has formed a UK subsidiary through which it will sell products directly to the market. The London-based operation, which will be headed by Francois Gary, will start up in the autumn and will initially sell MRI agents, Gullan Agerbak, director of the company's international subsidiaries division, told Clinica at the Rontgen Centenary congress in Birmingham last week.
You may also be interested in...
Common Regulatory Starting Point Means EU-UK Are On Track For Medtech MRA, Say German Firms
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
COVID-19 Vaccines Donated To Philippines Require Emergency Use Authorization
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Purespring Therapeutics: Pioneering Gene Therapy For Kidney Disorders
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: